Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In response the novel coronavirus emergency, the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has activated its Clinical Characterisation Protocol (CCP) for emerging infections in England and Scotland.

Coronavirus © Alissa Eckert, MS; Dan Higgins, MAM

The Clinical Characterisation Protocol (CCP) was prepared for just such an emergency. It provides an ethically approved framework for enrolling patients to a clinical study which will offer new insights into this emerging global threat.

The CCP facilitates the collection of standardised clinical data and samples on patients hospitalised with suspected or confirmed infection with novel coronavirus. This will inform the outbreak response and patient care, not just in the UK but internationally. With novel coronavirus patients now identified in the UK, the UK health research community is well-prepared to advance our understanding of this disease.

The Chief Investigator for the UK CCP is Professor Calum Semple at the University of Liverpool. The development of the CCP was led by Dr Kenneth Baillie at the University of Edinburgh. The CCP study is sponsored by the University of Oxford and ISARIC’s Global Support Centre is hosted by the University of Oxford. ISARIC’s Members have developed the CCP over a number of years.

The CCP is supported by the National Institute for Health Research (NIHR) and is now open to enrolment in NHS Trusts, including the network of high-containment clinical facilities where patients with novel coronavirus will be admitted in the early stages of the disease in the UK.

ISARIC is a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases. ISARIC’s mission is to generate and disseminate clinical research evidence for outbreak-prone infectious diseases, whenever and wherever they occur.

ISARIC is funded by the Wellcome Trust, the UK Department for International Development, and the Bill & Melinda Gates Foundation.

Similar stories

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Professor Trish Greenhalgh Highly Commended in the O²RB Excellence in Impact Awards 2021

Congratulations to Professor Trish Greenhalgh (Nuffield Department of Primary Care Health Sciences) who has been Highly Commended in the O²RB Excellence in Impact Awards 2021.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.